Marc Hedrick

Recent appearances

• 

  Why Brain Cancer Has Been Left Behind for 50 Years | Cerenome CEO Marc Hedrick & Russell Bradley

  October 01, 2026 · 📺 The Biohub

  Brain metastases and leptomeningeal disease are becoming more common as breast, lung and melanoma patients live longer, yet CNS cancer outcomes have lagged the rest of oncology for decades. Cerenome (formerly Plus Therapeutics) CEO Marc Hedrick, MD, and Russell Bradley explain why, and what an integrated approach to diagnosis, targeted radiation and data could change. In this episode of The BioHub by Avetix: Why CNS cancer is a "systems disease", and why single-point solutions keep failing How CNSide detects tumor cells in cerebrospinal fluid that standard CSF cytology misses Using tumor cel…

  Watch on YouTube ↗

• 

  Cerenome (NASDAQ: CNSY) Rebrand, formerly Plus Therapeutics | Fintech TV Exclusive

  August 19, 2026 · 📺 Cerenome

  Cerenome (NASDAQ: CNSY), formerly Plus Therapeutics (NASDAQ: PSTV), is advancing a new era of innovation in central nervous system (CNS) cancer through targeted therapeutics and precision diagnostics. In this Fintech TV exclusive, learn more about Cerenome’s corporate rebrand, our mission, and our approach to developing solutions designed to address some of the most challenging cancers affecting the brain and central nervous system. Discover how Cerenome is working to bring greater clarity to CNS cancer diagnosis and treatment through CNSide®, our cerebrospinal fluid diagnostic platform, and…

  Watch on YouTube ↗

• 

  Can Targeted Radiation Change the Future of Brain Cancer? | Dr. Marc Hedrick | Plus Therapeutics

  June 04, 2026 · 📺 Rare Connection

  Send us Fan Mail (https://www.buzzsprout.com/2204433/fa...) In this episode of Rare Connection, host Joanna Ball speaks with Dr. Marc Hedrick, President and CEO of Plus Therapeutics, about emerging technologies aimed at improving outcomes for patients with some of the most difficult-to-treat cancers affecting the central nervous system. Dr. Hedrick discusses leptomeningeal metastases (LM), a serious condition that occurs when cancer spreads to the membranes and fluid surrounding the brain and spinal cord, as well as recurrent glioblastoma, one of the most aggressive forms of brain cancer.…

  Watch on YouTube ↗

• 

  Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.

  March 15, 2026 · 📺 Life Science Connect

  On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq. We'll talk about Plus Therapeutics' diagnostic subsidiary, CNSide, and hear from Marc about recent FDA meetings and the agency's attitude toward novel radiotherapeutics. Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com --- #bu…

  Watch on YouTube ↗

• 

  Plus Therapeutics - $PSTV - Ep:032 - Nano Cap Podcast

  January 19, 2026 · 📺 Nano Cap Podcast

  In this episode, Dr. Marc Hedrick, CEO of Plus Therapeutics, shares his journey from academia to the biotech industry, discussing the innovative work being done in targeted radiotherapeutics for difficult-to-treat cancers. He elaborates on the importance of diagnostics in cancer treatment, the challenges of navigating the FDA approval process, and the complexities of scaling and manufacturing radiotherapeutic drugs. Dr. Hedrick also reflects on his motivations and the potential impact of their work on patient lives. Plus Therapeutics Website https://plustherapeutics.com/ Nano Cap Podca…

  Watch on YouTube ↗

• 

  Dr. Marc Hedrick, MD - CEO, Plus Therapeutics - Radiotherapeutics For Difficult-To-Treat CNS Cancers

  December 02, 2025 · 📺 Progress, Potential, and Possibilities

  Dr. Marc Hedrick, MD is President and CEO of Plus Therapeutics, Inc. ( https://plustherapeutics.com/ ), a U.S. clinical-stage pharmaceutical company, focused on developing innovative, targeted radiotherapeutics for adults and children with difficult-to-treat cancers of the central nervous system. The company’s lead programs focus on leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), leveraging image-guided local beta radiation and targeted drug delivery to improve outcomes. Additionally, Plus' subsidiary CNSide Diagnostics develops proprietary lab tests such as CNSide®, designed…

  Watch on YouTube ↗

• 

  CNSide® Secures Major Payor Coverage | Plus Therapeutics (NASDAQ: PSTV) at NYSE with StockTwits

  December 01, 2025 · 📺 Cerenome

  Plus Therapeutics (NASDAQ: PSTV) President & CEO, Marc Hedrick, MD, joined StockTwits’ Katie Perry at the New York Stock Exchange to discuss a major milestone: national coverage for the CNSide® CSF assay platform through both Humana and UnitedHealthcare. Dr. Hedrick highlights how CNSide® empowers clinicians with real-time, actionable insights for patients with leptomeningeal metastases and other central nervous system cancers. He also provides an update on REYOBIQ™ (rhenium [186Re] obisbemeda), the company’s targeted radiotherapeutic currently being evaluated in the ReSPECT clinical trials,…

  Watch on YouTube ↗

• 

  Inside the Latest in Targeted Radiotherapeutics with Plus Therapeutics CEO Dr. Marc Hedrick

  April 16, 2025 · 📺 Xtalks

  In this episode, Ayesha spoke with Marc Hedrick, MD, MBA, president and CEO of Plus Therapeutics, a company focused on developing a novel class of targeted radiotherapeutics. Prior to heading Plus Therapeutics, Dr. Hedrick served in a number of executive leadership roles including president, CEO and director at Cytori Therapeutics, and president and CEO of StemSource. Dr. Hedrick is a trained general, vascular and plastic surgeon. He is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as co-director of the…

  Watch on YouTube ↗

• 

  "Beyond the Podium: A Champion's Fight Against Brain Cancer" with Scott Hamilton & Marc Hedrick MD

  July 16, 2024 · 📺 Cerenome

  Exclusive Interview between Olympian & Brain Cancer Champion Scott Hamilton and Marc Hedrick, MD, "Beyond the Podium: A Champion's Fight Against Brain Cancer." In this inspiring interview, Olympic figure skater Scott Hamilton, founder of Scott Hamilton CARES Foundation, shares the story of his health complications and cancer journey with Marc Hedrick, MD and CEO of Plus Therapeutics, as both discuss advancing research and care for the glioblastoma and brain cancer communities in honor of Glioblastoma Awareness Day 2024. During the interview, Scott Hamilton and Marc Hedrick, MD, reflect on th…

  Watch on YouTube ↗

• 

  Plus Therapeutics at the Benzinga Virtual Healthcare Summit

  March 25, 2024 · 📺 Cerenome

  This segment interviews Plus Therapeutics' President & CEO Dr. Marc Hedrick, MD, MBA at the Benzinga Virtual Healthcare Summit, a forward-thinking virtual event featuring leading companies, healthcare visionaries, renowned analysts, asset managers, and thought leaders. The discussion focuses on current developments in the company’s clinical pipeline with a particular focus on the potential of lead asset rhenium (Re-186) obisbemeda in leptomeningeal metastases and recurrent glioblastoma. Beyond clinical progress, they address the benefits of developing companion diagnostics, recent development…

  Watch on YouTube ↗

• 

  Fireside Chat with Plus Therapeutics CEO

  March 12, 2024 · 📺 Cerenome

  March 12, 2024: Join a fireside chat with Dr. Marc Hedrick, MD, MBA, President & CEO of Plus Therapeutics, hosted by JonesResearch. The discussion focuses on current developments in the company’s clinical pipeline with a particular focus on the potential of lead asset rhenium (Re-186) obisbemeda in leptomeningeal metastases (LM). Beyond clinical progress, they address the benefits of developing companion diagnostics, the company’s funding from/collaboration with the Cancer Prevention and Research Institute of Texas (CPRIT), and recent developments in the radiopharmaceutical field. About Plu…

  Watch on YouTube ↗

• 

  Novel Targeted Cancer Treatment: Plus Therapeutics President and CEO Marc Hedrick, Live from NYSE

  September 19, 2023 · 📺 IPO Edge

  IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Marc Hedrick, M.D., President and CEO of Plus Therapeutics, Inc. (Nasdaq: PSTV). Dr. Hedrick spoke to  IPO Edge Editor-in-Chief John Jannarone about its novel targeted radio-therapeutics treatment for central nervous system cancer using the latest technology, its future potential to treat any form of cancer in the brain and the spinal cord at any stage, among other topics.

  Watch on YouTube ↗